bluebird bio, Inc. (LON:0HOH)
London
· Delayed Price · Currency is GBP · Price in USD 3.900
0.00 (0.00%)
At close: Mar 10, 2025
bluebird bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 103.95 | 83.8 | 29.07 | 2.74 | 2.85 | - | Upgrade
|
| Other Revenue | - | 0.01 | 0.43 | 0.86 | 0.81 | - | Upgrade
|
| Revenue | 103.95 | 83.81 | 29.5 | 3.6 | 3.66 | - | Upgrade
|
| Revenue Growth (YoY) | 127.51% | 184.12% | 720.04% | -1.77% | - | - | Upgrade
|
| Cost of Revenue | 75.75 | 89.38 | 33.53 | 10.08 | 354.8 | 319.31 | Upgrade
|
| Gross Profit | 28.19 | -5.57 | -4.03 | -6.48 | -351.14 | -319.31 | Upgrade
|
| Selling, General & Admin | 173.98 | 190.05 | 190.38 | 169.47 | 209.97 | 239.95 | Upgrade
|
| Research & Development | 64.72 | 72.08 | 142.79 | 171.3 | - | - | Upgrade
|
| Other Operating Expenses | - | - | -92.93 | -102 | - | - | Upgrade
|
| Operating Expenses | 238.71 | 262.13 | 240.23 | 238.77 | 209.97 | 239.95 | Upgrade
|
| Operating Income | -210.51 | -267.7 | -244.26 | -245.25 | -561.11 | -559.26 | Upgrade
|
| Interest Expense | -23.47 | -22.58 | -16.35 | -6.32 | - | - | Upgrade
|
| Interest & Investment Income | 6.25 | 8.22 | 9.87 | 1.03 | 0.88 | 5.77 | Upgrade
|
| Other Non Operating Income (Expenses) | 33.78 | 44.18 | 38.71 | 28.39 | -1.7 | 0.34 | Upgrade
|
| EBT Excluding Unusual Items | -193.95 | -237.88 | -212.04 | -222.15 | -561.93 | -553.15 | Upgrade
|
| Merger & Restructuring Charges | -5.86 | -2.76 | - | -4.94 | -29.81 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -3.14 | 29.36 | -7.22 | Upgrade
|
| Pretax Income | -199.81 | -240.65 | -212.04 | -230.23 | -562.38 | -560.37 | Upgrade
|
| Income Tax Expense | 0.17 | 0.07 | -0.13 | 0.12 | 0.26 | 0.69 | Upgrade
|
| Earnings From Continuing Operations | -199.98 | -240.72 | -211.91 | -230.34 | -562.64 | -561.06 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -256.74 | -57.64 | Upgrade
|
| Net Income | -199.98 | -240.72 | -211.91 | -230.34 | -819.38 | -618.7 | Upgrade
|
| Net Income to Common | -199.98 | -240.72 | -211.91 | -230.34 | -819.38 | -618.7 | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 5 | 4 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 5 | 4 | 3 | 3 | Upgrade
|
| Shares Change (YoY) | 46.73% | 76.45% | 39.75% | 14.04% | 10.83% | 12.66% | Upgrade
|
| EPS (Basic) | -20.59 | -24.84 | -38.59 | -58.62 | -237.81 | -199.01 | Upgrade
|
| EPS (Diluted) | -20.59 | -24.84 | -38.59 | -58.62 | -237.81 | -199.01 | Upgrade
|
| Free Cash Flow | -230.47 | -262.62 | -239.24 | -324.43 | -650.14 | -499.34 | Upgrade
|
| Free Cash Flow Per Share | -23.73 | -27.11 | -43.57 | -82.57 | -188.69 | -160.62 | Upgrade
|
| Gross Margin | 27.12% | -6.65% | -13.66% | -180.15% | - | - | Upgrade
|
| Operating Margin | -202.52% | -319.42% | -828.09% | -6818.04% | -15322.36% | - | Upgrade
|
| Profit Margin | -192.39% | -287.23% | -718.42% | -6403.73% | -22375.15% | - | Upgrade
|
| Free Cash Flow Margin | -221.72% | -313.36% | -811.05% | -9019.38% | -17753.74% | - | Upgrade
|
| EBITDA | -149.2 | -206.46 | -215.74 | -236.9 | -555.65 | -553.63 | Upgrade
|
| EBITDA Margin | -143.53% | -246.35% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 61.32 | 61.24 | 28.53 | 8.34 | 5.45 | 5.63 | Upgrade
|
| EBIT | -210.51 | -267.7 | -244.26 | -245.25 | -561.11 | -559.26 | Upgrade
|
| EBIT Margin | -202.52% | - | - | - | - | - | Upgrade
|
| Revenue as Reported | 103.95 | 83.81 | 29.5 | 3.6 | 3.66 | - | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.